Navigation Links
New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
Date:3/15/2008

week double-blind period, no treatment effect was seen in adjusted mean height increase plus or minus SE (p=0.4086) between children treated with Nasacort AQ (0.62 plus or minus 0.224 cm; n=217) and those receiving placebo (0.38 plus or minus 0.225 cm; n=216). After the 6-month open label period (Visit 8), the adjusted mean increase in height was 3.62 + 0.693 cm. Based on the Centers for Disease Control and Prevention (CDC) growth standards, the distribution of patients by height-for-age percentile remained constant from Visit 1 to Visit 8. At Visit 1, 6.2% of children were in the <5 percentile (n=22) versus 5.4% (n=19) at Visit 8. Similarly, at Visit 1, 6.5% of children (n=23) were within the >95th percentile versus 7.4% at Visit 8. At both Visit 1 and Visit 8, 87.3% of children (n=308) fell between the 5th and 95th percentile.

The study was submitted as part of a supplemental New Drug Application (sNDA) for Nasacort AQ in children aged 2 - 5 years, which was recently accepted for review by the FDA.

About CDC Growth Charts

The CDC growth charts consist of a series of percentile curves that illustrate the distribution of selected body measurements in U.S. children. The charts provide health professionals with a tool to compare growth in infants, children, and adolescents with a nationally representative reference based on children of all ages and racial or ethnic groups. The CDC growth charts were updated in 2000.

About Allergic Rhinitis

Allergic rhinitis is a swelling of the nasal passages, usually accompanied by sneezing, watery nasal discharge and itching of the nose and eyes. This medical condition is caused by an allergic reaction to allergens such as house dust, animal dander, or pollen. On any given day, 10,000 American children miss school because of allergic rhinitis, for a total of 2 million lost school days.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops an
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
2. Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
3. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. PARI Nebulizer & Compressor Used Exclusively in Inspires Phase 3 CF Trial
7. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
8. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
9. Multi Merci Trial Results Published in Peer Reviewed Journal
10. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender ... (NASDAQ: VPHM).   As a result of the ... and Shire expects to complete the tender offer on January ... the satisfaction of all of the remaining conditions to the ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors ... be able to protect their most important ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) ... Medical Device Industry, it steadfastly remains one ... cases involving IP infringement. This litigious nature ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ... less than 10 bps, yet are surprisingly capable in ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Nasdaq: NVGN ), announced today that following ... held on 7 May, 2012, its Board of Directors ... Marshall Edwards, Inc. ("MEI") under the MEI rights offering ... rights that have not been otherwise exercised by MEI ...
... 2012  Marshall Edwards, Inc. (Nasdaq: MSHL ), ... novel therapeutics targeting cancer metabolism, announced that its majority ... million of Units, subject to availability, in Marshall Edwards, ... Novogen stockholders in Sydney on Monday. Pursuant ...
Cached Medicine Technology:Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering 2Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering 2Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... 30 (HealthDay News) -- Parents who smoke are more likely to ... but their chances of success aren,t any better than normal, a ... an important role in helping these parents quit smoking, said the ... included 1,112 children who lived with at least one person who ...
... health problems have higher mortality rates than patients without ... 30 in the Journal of the National Cancer ... heart attack and other heart-related problems, chronic obstructive pulmonary ... that comorbidities as a group are associated with poorer ...
... consider the impact of gender on patient outcomes in major ... found that women are more likely to survive after the ... comparing women before menopause with men of the same age. ... Surgical Research in a paper titled "The Battle of ...
... By Randy Dotinga HealthDay Reporter , THURSDAY, June ... it is to remember things that never happened, especially if ... British and Israeli researchers used a novel false-memory test and ... About 70 percent of those who took part in the ...
... Johns Hopkins have provided more clues to one of the ... of cellular DNA, called telomeres, lengthen instead of shorten. ... Express, the Johns Hopkins researchers say they have identified ... Telomeres contain repeated sequences of DNA that, in normal ...
... new study published in the American Journal of Transplantation ... skin cancers, including cutaneous squamous cell carcinoma and melanoma, ... they need immune medications to keep their body from ... they experience as a result of the medications can ...
Cached Medicine News:Health News:A Child's Surgery May Prompt Parents to Try to Quit Smoking 2Health News:Worse outcomes for older breast cancer patients with other health problems 2Health News:Women win out in gastrointestinal surgery 2Health News:Group-Think Can Influence Your Memory, Research Shows 2Health News:Telomeres: 2 genes linked to why they stretch in cancer cells 2Health News:Telomeres: 2 genes linked to why they stretch in cancer cells 3
For the quantitative determination of total cholesterol in human serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products: